These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23866421)

  • 41. Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature.
    Toyonaga T; Nakase H; Matsuura M; Minami N; Yamada S; Honzawa Y; Hukata N; Yoshino T; Chiba T; Okazaki K
    Digestion; 2013; 88(4):217-21. PubMed ID: 24247154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of severe Behçet's disease with anti-TNF-alpha: infliximab. A case report].
    Andreu M; Ramanoelina J; Fajnkuchen F; Mouthon L; Cohen P; Laroche L; Guillevin L
    Ann Med Interne (Paris); 2002 Oct; 153(6):414-5. PubMed ID: 12486393
    [No Abstract]   [Full Text] [Related]  

  • 43. Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet's disease.
    Kramer M; Ehrlich R; Snir M; Friling R; Mukamel M; Weinberger D; Axer-Siegel R
    Am J Ophthalmol; 2004 Oct; 138(4):666-7. PubMed ID: 15488806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
    Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract]   [Full Text] [Related]  

  • 46. Infliximab for refractory oral ulcers.
    Ryu HJ; Seo MR; Choi HJ; Baek HJ
    Am J Otolaryngol; 2014; 35(5):664-8. PubMed ID: 24962948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adalimumab for sight-threatening uveitis in Behçet's disease.
    Mushtaq B; Saeed T; Situnayake RD; Murray PI
    Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
    Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
    Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A controlled trial of azathioprine in Behçet's syndrome.
    Yazici H; Pazarli H; Barnes CG; Tüzün Y; Ozyazgan Y; Silman A; Serdaroğlu S; Oğuz V; Yurdakul S; Lovatt GE
    N Engl J Med; 1990 Feb; 322(5):281-5. PubMed ID: 2404204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Behçet's disease of the eyes].
    de Vries J; Baarsma GS; van der Loos TL
    Ned Tijdschr Geneeskd; 1990 Jan; 134(3):124-6. PubMed ID: 2300227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Ocular Behcet's disease: procedural aspects].
    Postelmans L; Verougstraete C; Caspers-Velu L
    Bull Soc Belge Ophtalmol; 2001; (280):7-11. PubMed ID: 11486467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
    Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
    Capella MJ; Foster CS
    Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment.
    Baki K; Villiger PM; Jenni D; Meyer T; Beer JH
    Ann Rheum Dis; 2006 Nov; 65(11):1531-2. PubMed ID: 17038456
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M; Cinal A; Topcu N; Demirok A
    Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
    [No Abstract]   [Full Text] [Related]  

  • 57. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
    Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
    Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease.
    Triolo G; Vadalà M; Accardo-Palumbo A; Ferrante A; Ciccia F; Giardina E; Citarrella P; Lodato G; Licata G
    Ann Rheum Dis; 2002 Jun; 61(6):560-1. PubMed ID: 12006336
    [No Abstract]   [Full Text] [Related]  

  • 59. Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature.
    Mainini G; Di Donna MC; Esposito E; Ercolano S; Correa R; Stradella L; Della Gala A; De Franciscis P
    Clin Exp Obstet Gynecol; 2014; 41(2):205-7. PubMed ID: 24779253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrent oral and oculogenital ulcerations (Behçet's syndrome).
    Rapidis AD; Langdon JD; Patel MF
    Oral Surg Oral Med Oral Pathol; 1976 Apr; 41(4):457-66. PubMed ID: 1063347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.